TD Asset Management Inc Grows Holdings in Bausch Health Companies Inc. (NYSE:BHC)

TD Asset Management Inc grew its stake in shares of Bausch Health Companies Inc. (NYSE:BHC) by 1.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 967,716 shares of the company’s stock after purchasing an additional 17,113 shares during the quarter. TD Asset Management Inc’s holdings in Bausch Health Companies were worth $7,752,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its holdings in Bausch Health Companies by 57.4% during the 2nd quarter. Parallel Advisors LLC now owns 3,262 shares of the company’s stock worth $26,000 after acquiring an additional 1,189 shares in the last quarter. Atria Wealth Solutions Inc. boosted its holdings in shares of Bausch Health Companies by 13.4% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 30,377 shares of the company’s stock valued at $243,000 after buying an additional 3,600 shares during the period. Barclays PLC boosted its holdings in shares of Bausch Health Companies by 198.5% in the 2nd quarter. Barclays PLC now owns 954,226 shares of the company’s stock valued at $7,633,000 after buying an additional 634,551 shares during the period. Bank of Nova Scotia acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at about $165,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Bausch Health Companies by 71.3% in the 2nd quarter. Van ECK Associates Corp now owns 610,556 shares of the company’s stock valued at $4,884,000 after buying an additional 254,075 shares during the period. 74.56% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 6,685 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $8.28, for a total transaction of $55,351.80. Following the sale, the executive vice president now directly owns 385,213 shares in the company, valued at approximately $3,189,563.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 13.75% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BHC. Royal Bank of Canada lifted their price target on shares of Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Monday, July 24th. Jefferies Financial Group raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and lifted their price target for the company from $9.00 to $16.00 in a report on Wednesday, September 20th. Finally, StockNews.com lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th.

Bausch Health Companies Trading Up 2.1 %

Bausch Health Companies stock opened at $7.05 on Tuesday. The company has a quick ratio of 0.89, a current ratio of 1.20 and a debt-to-equity ratio of 74.20. The firm has a 50-day moving average price of $7.56 and a two-hundred day moving average price of $7.91. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -2.67 and a beta of 0.98. Bausch Health Companies Inc. has a 52-week low of $5.57 and a 52-week high of $10.23.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.